What are the terms of the ACLX merger?
Under the definitive agreement and plan of merger between Gilead Sciences and Arcellx Inc (ACLX), Gilead acquired Arcellx through a structured two-step transaction consisting of a cash tender offer followed by a merger. Shareholders of Arcellx received $115.00 in cash per share, plus one non-transferable contingent value right (CVR) per share, bringing the total implied equity value of the transaction to approximately $7.8 billion. Each CVR entitles the holder to an additional conditional cash payment of $5.00 upon the achievement of a specific commercial milestone, namely when cumulative worldwide net sales of their joint lead multiple myeloma treatment candidate, anito-cel, reach $6.0 billion by December 31, 2029. The transaction was fully backed by major supporting stockholders representing a notable percentage of outstanding shares, required standard regulatory clearances, and was successfully completed without any external financing contingencies.
Related FAQs
The share price of Arcellx, Inc. (listed on the NASDAQ global market under the ticker symbol ACLX) is approximately 115.07 USD.
Arcellx completed its definitive merger agreement with Gilead Sciences, under which Gilead acquired the company for a substantial cash price per share plus a contingent value right.
Gilead Sciences has significantly expanded its antiviral, oncology, and cell therapy pipeline through major strategic corporate acquisitions.
Yes, First Security Bank currently operates as a division of Glacier Bank, which is a key component of the regional bank holding company Glacier Bancorp, Inc.
Gilead Sciences owns and commercializes a robust portfolio of breakthrough antiviral, oncology, and inflammatory therapeutics that have transformed global healthcare.
The regenerative medicine and stem cell therapeutics sector features innovative biotechnology enterprises pioneering advanced clinical treatments for degenerative diseases, autoimmune disorders, and trauma recovery.
Identifying premier equities within the regenerative medicine space involves targeting biotechnology pioneers with advanced late-stage clinical pipelines and strong patent portfolios.
The acronym ACLX serves as the NASDAQ stock ticker symbol for Arcellx, Inc.
Assessing Axcelis Technologies stock as an investment involves weighing its strong positioning in the semiconductor supply chain against cyclical industry downturns and valuation shifts.
Determining whether Arcellx (ACLX) represents a favorable buy recommendation requires examining its clinical-stage biotechnology pipeline, particularly its innovative cell therapies targeting cancer and severe autoimmune conditions.
Arcellx, Inc. is a clinical-stage biotechnology company dedicated to reimagining cell therapy through the development of innovative immunotherapies targeting cancer and other incurable diseases.